While total IgE levels are not always predictive of asthma severity, they are essential for determining eligibility for omalizumab therapy, which is approved for patients with moderate-to-severe allergic asthma and total IgE levels between 30 and 700 IU/mL. The gene discussed is IGHE; the disease is allergic asthma.